Kubota Pharmaceutical Holdings Co., Ltd.
Tokyo Stock ExchangeTotal Valuation
Kubota Pharmaceutical Holdings Co., Ltd. carries a market capitalization of 5.43B, placing it among publicly traded companies globally. Its enterprise value stands at 2.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.43B |
| Enterprise Value | 2.30B |
Share Statistics
Kubota Pharmaceutical Holdings Co., Ltd. currently has 56.30M shares outstanding.
| Shares Outstanding | 56.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 127.97, and the price-to-book ratio stands at -0.17.
| PE Ratio | N/A |
| PS Ratio | 127.97 |
| PB Ratio | -0.17 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | -3.43 |
| P/OCF Ratio | -3.21 |
Enterprise Valuation
| EV / Sales | 70.94 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Kubota Pharmaceutical Holdings Co., Ltd. maintains a current ratio of 8.76, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.50, indicating elevated leverage, while an interest coverage ratio of -165.42 demonstrates limited ability to service its debt obligations.
| Current Ratio | 8.76 |
| Quick Ratio | 8.27 |
| Debt / Equity | 10.50 |
| Debt / EBITDA | -0.15 |
| Interest Coverage | -165.42 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -46.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.22 |
Stock Price Statistics
Kubota Pharmaceutical Holdings Co., Ltd.'s stock has gained approximately 80.85106% over the past 52 weeks. The 50-day moving average sits at 68.84, while the 200-day moving average is 82.18.
| Beta (5Y) | N/A |
| 52-Week Price Change | 80.85106% |
| 50-Day Moving Average | 68.84 |
| 200-Day Moving Average | 82.18 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kubota Pharmaceutical Holdings Co., Ltd. generated 32.44M in revenue and converted that into -1.41B in net income, yielding earnings per share of -25.20. EBITDA reached -1.43B, while operating income came in at -1.43B.
| Revenue | 32.44M |
| Gross Profit | 24.71M |
| Operating Income | -1.43B |
| Pretax Income | -1.41B |
| Net Income | -1.41B |
| EBITDA | -1.43B |
| EBIT | -1.43B |
| Earnings Per Share (EPS) | -25.20 |
Balance Sheet
Kubota Pharmaceutical Holdings Co., Ltd. holds 2.06B in cash and equivalents against 213.03M in total debt, resulting in a net debt position of -1.98B. Total book value stands at -24.37B, with working capital of 1.94B providing operational flexibility.
| Cash & Cash Equivalents | 2.06B |
| Total Debt | 213.03M |
| Net Debt | -1.98B |
| Equity (Book Value) | -24.37B |
| Book Value Per Share | -434.45 |
| Working Capital | 1.94B |
Cash Flow
Kubota Pharmaceutical Holdings Co., Ltd. produced -1.29B in operating cash flow over the past twelve months. After subtracting -83.39M in capital expenditures, free cash flow totaled -1.38B - equivalent to -24.54 per share.
| Operating Cash Flow | -1.29B |
| Capital Expenditures | -83.39M |
| Free Cash Flow | -1.38B |
| FCF Per Share | -24.54 |
Margins
Kubota Pharmaceutical Holdings Co., Ltd. operates with a gross margin of 76.16, reflecting its pricing power and cost economics. The operating margin of -4,414.04 and net profit margin of -4,358.35 provide insight into operational efficiency.
| Gross Margin | 76.16 |
| Operating Margin | -4,414.04 |
| Pretax Margin | -4,358.35 |
| Profit Margin | -4,358.35 |
| EBITDA Margin | -4,414.04 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.01 |
| FCF Yield | -29.15 |
Scores
Kubota Pharmaceutical Holdings Co., Ltd. posts an Altman Z-Score of -7.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.65 |